HRP20150281T1 - Prevencija i lijeäśenje stanja oka povezanih sa sustavom komplementa - Google Patents
Prevencija i lijeäśenje stanja oka povezanih sa sustavom komplementa Download PDFInfo
- Publication number
- HRP20150281T1 HRP20150281T1 HRP20150281AT HRP20150281T HRP20150281T1 HR P20150281 T1 HRP20150281 T1 HR P20150281T1 HR P20150281A T HRP20150281A T HR P20150281AT HR P20150281 T HRP20150281 T HR P20150281T HR P20150281 T1 HRP20150281 T1 HR P20150281T1
- Authority
- HR
- Croatia
- Prior art keywords
- antibody
- antigen
- factor
- binding fragment
- antagonist
- Prior art date
Links
- 230000002265 prevention Effects 0.000 title claims 2
- 230000000295 complement effect Effects 0.000 title 1
- 239000000427 antigen Substances 0.000 claims 16
- 102000036639 antigens Human genes 0.000 claims 16
- 108091007433 antigens Proteins 0.000 claims 16
- 239000012634 fragment Substances 0.000 claims 15
- 239000005557 antagonist Substances 0.000 claims 11
- 230000004154 complement system Effects 0.000 claims 6
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 3
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims 2
- 206010064930 age-related macular degeneration Diseases 0.000 claims 2
- 201000005667 central retinal vein occlusion Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000002780 macular degeneration Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 208000004644 retinal vein occlusion Diseases 0.000 claims 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 1
- 206010055665 Corneal neovascularisation Diseases 0.000 claims 1
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 201000002563 Histoplasmosis Diseases 0.000 claims 1
- 208000007135 Retinal Neovascularization Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims 1
- 201000000159 corneal neovascularization Diseases 0.000 claims 1
- 208000001309 degenerative myopia Diseases 0.000 claims 1
- 230000004340 degenerative myopia Effects 0.000 claims 1
- 201000011190 diabetic macular edema Diseases 0.000 claims 1
- 208000011325 dry age related macular degeneration Diseases 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 208000006542 von Hippel-Lindau disease Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
Claims (12)
1. Antagonist protutijela anti-Faktora D ili njegovog fragmenta koji se veže na antigen, naznačen time, da se upotrebljava u postupku prevencije ili liječenja stanja ljudskog oka, povezanih sa sustavom komplementa, pri čemu je to protutijelo ili njegov fragment koji se veže na atigen, slijedeće/i:
i. protutijelo 20D12 koje ima sekvence slabog i jakog lanca prikazane u SEQ ID NO:1 i SEQ ID NO:2, ili njegov fragment koji se veže na antigen; ili
ii. protutijelo ili njegov fragment koji se veže na antigen, koji se natječe u križno-blokiranom testiranju s protutijelom iz točke (i), u vezanju na epitop spojen preko protutijela iz točke (i), te koji se veže na djelatni centar Faktora D i/ili se veže na epitop koji uključuje ostatke djelatnih centara Faktora D.
2. Antagonist protutijela anti-Faktora D ili njegovog fragmenta koji se veže na antigen za uporabu prema zahtjevu 1, naznačen time, da je to varijanta protutijela ili njegovog fragmenta koji se veže na antigen iz točke (i), koja ima najmanje 90% identičnosti sekvence prema njegovim sekvencama varijabilne domene.
3. Antagonist protutijela anti-Faktora D ili njegovog fragmenta koji se veže na antigen za uporabu prema zahtjevu 1 ili zahtjevu 2, naznačen time, da on obuhvaća sekvence CDR jakog i slabog lanca (definirane prema Kabatu) od protutijela iz točke (i).
4. Antagonist protutijela anti-Faktora D ili njegovog fragmenta koji se veže na antigen za uporabu prema bilo kojem od prethodnih zahtjeva, naznačen time, da je to ljudsko protutijelo, humanizirano protutijelo ili kimerno protutijelo, ili njegov fragment koji se veže na antigen.
5. Antagonist fragmenta protutijela anti-Faktora D, koji se veže na antigen za uporabu prema bilo kojem od prethodnih zahtjeva, naznačen time, da je odabran iz skupine koju čine Fab, Fab', F(ab')2, scFv, (scFv)2, linearna protutijela, molekule protutijela jednostrukog lanca, minitijela, dijatijela, i multispecifična protutijela stvorena iz fragmenata protutijela.
6. Antagonist fragmenta protutijela anti-Faktora D, koji se veže na antigen za uporabu prema zahtjevu 5, naznačen time, da je to fragment kako slijedi: Fab, Fab', F(ab')2, scFv, ili (scFv)2.
7. Antagonist protutijela anti-Faktora D ili njegovog fragmenta koji se veže na antigen za uporabu prema bilo kojem od prethodnih zahtjeva, naznačen time, da se on veže na ljudski Faktor D uz vrijednost Kd koja nije veća od 5 nM.
8. Antagonist protutijela anti-Faktora D ili njegovog fragmenta koji se veže na antigen za uporabu prema bilo kojem od prethodnih zahtjeva, naznačen time, da je stanje oka povezano sa sustavom komplementa, odabrano iz skupine koju čine senilna degeneracija makule (AMD), koroidna neovaskularizacija (CNV), uveitis, dijabetičke retinopatije i ostale ishemijske retinopatije, dijabetički edem makule, patološka miopija, Hippel-Lindau-bolest, histoplasmoza oka, okluzija centralne vene retine (CRVO), neovaskularizacija kornee i neovaskularizacija retine.
9. Antagonist protutijela anti-Faktora D ili njegovog fragmenta koji se veže na antigen za uporabu prema zahtjevu 8, naznačen time, da navedeno stanje oka povezano sa sustavom komplementa je suho AMD-stanje.
10. Antagonist protutijela anti-Faktora D ili njegovog fragmenta koji se veže na antigen za uporabu prema zahtjevu 8, naznačen time, da navedeno stanje oka povezano sa sustavom komplementa je vlažno AMD-stanje.
11. Uporaba antagonista protutijela anti-Faktora D ili njegovog fragmenta koji se veže na antigen prema bilo kojem od zahtjeva 1 do 7, naznačena time, da je za proizvodnju lijeka za liječenje stanja oka povezanog sa sustavom komplementa.
12. Uporaba prema zahtjevu 11, naznačena time, da je za proizvodnju lijeka za liječenje stanja oka povezanog sa sustavom komplementa, definiranog prema bilo kojem od zahtjeva 8 do 10.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93979107P | 2007-05-23 | 2007-05-23 | |
| EP08756130.4A EP2152755B1 (en) | 2007-05-23 | 2008-05-22 | Prevention and treatment of complement-associated eye conditions |
| PCT/US2008/064526 WO2008147883A1 (en) | 2007-05-23 | 2008-05-22 | Prevention and treatment of complement-associated eye conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20150281T1 true HRP20150281T1 (hr) | 2015-04-10 |
Family
ID=39638868
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20150281AT HRP20150281T1 (hr) | 2007-05-23 | 2015-03-12 | Prevencija i lijeäśenje stanja oka povezanih sa sustavom komplementa |
Country Status (28)
| Country | Link |
|---|---|
| US (6) | US8007791B2 (hr) |
| EP (1) | EP2152755B1 (hr) |
| JP (4) | JP5416695B2 (hr) |
| KR (1) | KR101540126B1 (hr) |
| CN (3) | CN104367999A (hr) |
| AR (1) | AR066660A1 (hr) |
| AU (1) | AU2008256835B2 (hr) |
| BR (1) | BRPI0811142A8 (hr) |
| CA (1) | CA2683498A1 (hr) |
| CL (1) | CL2008001498A1 (hr) |
| CY (1) | CY1116062T1 (hr) |
| DK (1) | DK2152755T3 (hr) |
| ES (1) | ES2533242T3 (hr) |
| HK (2) | HK1139161A1 (hr) |
| HR (1) | HRP20150281T1 (hr) |
| IL (2) | IL201476A (hr) |
| MX (1) | MX2009012422A (hr) |
| PE (1) | PE20090294A1 (hr) |
| PH (1) | PH12013500992B1 (hr) |
| PL (1) | PL2152755T3 (hr) |
| PT (1) | PT2152755E (hr) |
| RS (1) | RS53901B1 (hr) |
| RU (2) | RU2522976C2 (hr) |
| SG (1) | SG10201401404RA (hr) |
| SI (1) | SI2152755T1 (hr) |
| TW (2) | TWI419704B (hr) |
| WO (1) | WO2008147883A1 (hr) |
| ZA (1) | ZA200907028B (hr) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1287364B1 (en) * | 2000-04-29 | 2008-10-22 | University Of Iowa Research Foundation | Diagnostics and therapeutics for macular degeneration-related disorders |
| NZ594285A (en) | 2005-11-04 | 2013-02-22 | Genentech Inc | USE OF COMPLEMENT PATHWAY INHIBITOR ANTIBODY AGAINST C5a TO TREAT OCULAR DISEASES |
| KR20160092061A (ko) | 2006-11-02 | 2016-08-03 | 제넨테크, 인크. | 인간화 항-ｄ 인자 항체 |
| AR066660A1 (es) * | 2007-05-23 | 2009-09-02 | Genentech Inc | Prevencion y tratamiento de condiciones del ojo asociadas con su complemento |
| CR20170001A (es) | 2008-04-28 | 2017-08-10 | Genentech Inc | Anticuerpos anti factor d humanizados |
| JP5564045B2 (ja) * | 2008-09-02 | 2014-07-30 | ノバルティス アーゲー | 二環式キナーゼ阻害剤 |
| US8623395B2 (en) | 2010-01-29 | 2014-01-07 | Forsight Vision4, Inc. | Implantable therapeutic device |
| SG2014007389A (en) | 2009-01-29 | 2014-04-28 | Forsight Vision4 Inc | Posterior segment drug delivery |
| WO2010129609A2 (en) * | 2009-05-07 | 2010-11-11 | The Regents Of The University Of California | Antibodies and methods of use thereof |
| US20110165648A1 (en) | 2009-11-04 | 2011-07-07 | Menno Van Lookeren Campagne | Co-crystal structure of factor D and anti-factor D antibody |
| CN103209664A (zh) * | 2010-08-05 | 2013-07-17 | 弗赛特影像4股份有限公司 | 可植入的治疗装置 |
| MX348025B (es) | 2010-11-01 | 2017-05-24 | Genentech Inc * | Prediccion del paso a degeneracion macular avanzada relacionada con la edad utilizando una puntuacion poligenica. |
| MX347391B (es) | 2011-01-04 | 2017-04-25 | Novartis Ag | Compuestos de indol o análogos de los mismos útiles para el tratamiento de degeneración macular relacionada con la edad (amd). |
| DK2668210T3 (da) | 2011-01-26 | 2020-08-24 | Celldex Therapeutics Inc | Anti-kit antistoffer og anvendelser deraf |
| JP6209605B2 (ja) | 2012-06-28 | 2017-10-04 | ノバルティス アーゲー | ピロリジン誘導体、および補体経路調節因子としてのその使用 |
| CN105121429B (zh) | 2012-06-28 | 2017-12-12 | 诺华股份有限公司 | 补体途径调节剂和其用途 |
| JP6154897B2 (ja) | 2012-06-28 | 2017-06-28 | ノバルティス アーゲー | ピロリジン誘導体、および補体経路調節因子としてのその使用 |
| EP2867227B1 (en) | 2012-06-28 | 2018-11-21 | Novartis AG | Complement pathway modulators and uses thereof |
| WO2014002054A1 (en) | 2012-06-28 | 2014-01-03 | Novartis Ag | Pyrrolidine derivatives and their use as complement pathway modulators |
| KR20150036481A (ko) | 2012-07-12 | 2015-04-07 | 노파르티스 아게 | 보체 경로 조절제 및 그의 용도 |
| JP6307075B2 (ja) | 2012-07-25 | 2018-04-18 | セルデックス セラピューティクス，インコーポレーテッド | 抗ｋｉｔ抗体及びその使用 |
| WO2014120555A1 (en) | 2013-01-31 | 2014-08-07 | The Regents Of The University Of California | Antibodies specific for urokinase-type plasminogen activator and methods of use thereof |
| US9526654B2 (en) | 2013-03-28 | 2016-12-27 | Forsight Vision4, Inc. | Ophthalmic implant for delivering therapeutic substances |
| CR20160132A (es) | 2013-08-12 | 2016-08-25 | Genentech Inc | Composiciones y método para tratar condiciones asociadas con el complemento |
| EP3054965B1 (en) * | 2013-10-07 | 2021-04-14 | Massachusetts Eye & Ear Infirmary | Anti-factor d antibody for use in preventing or reducing retinal detachment |
| AU2014339890A1 (en) * | 2013-10-25 | 2016-06-02 | Children's Medical Center Corporation | Methods of treating or preventing vascular diseases of the retina |
| MX2016014160A (es) * | 2014-05-01 | 2017-02-16 | Genentech Inc | Variantes del anticuerpo anti-factor d y sus usos. |
| WO2015179737A2 (en) | 2014-05-23 | 2015-11-26 | Kolltan Pharmaceuticals, Inc. | Treatment of eosinophil or mast cell related disorders |
| CA2998500A1 (en) * | 2015-09-23 | 2017-03-30 | Sangamo Therapeutics, Inc. | Htt repressors and uses thereof |
| WO2017075212A1 (en) | 2015-10-30 | 2017-05-04 | Genentech, Inc. | Anti-htra1 antibodies and methods of use thereof |
| EP3666901A1 (en) | 2015-10-30 | 2020-06-17 | F. Hoffmann-La Roche AG | Methods of measuring factor d activity and potency of factor d inhibitors |
| WO2017075252A1 (en) * | 2015-10-30 | 2017-05-04 | Genentech, Inc. | Anti-factor d antibody variant conjugates and uses thereof |
| JP2018534930A (ja) * | 2015-10-30 | 2018-11-29 | ジェネンテック， インコーポレイテッド | 抗ｄ因子抗体及びコンジュゲート |
| JP6771568B2 (ja) | 2015-12-23 | 2020-10-21 | グリーンオヴェイション・バイオテック・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＧｒｅｅｎｏｖａｔｉｏｎ Ｂｉｏｔｅｃｈ Ｇｍｂｈ | 補体活性化を抑制するポリペプチド |
| AU2017210042B2 (en) | 2016-01-20 | 2021-01-21 | 396419 B.C. Ltd. | Compositions and methods for inhibiting Factor D |
| WO2018136827A1 (en) | 2017-01-20 | 2018-07-26 | Vitrisa Therapeutics, Inc. | Stem-loop compositions and methods for inhibiting factor d |
| CN110461879B (zh) * | 2017-02-10 | 2024-03-29 | 宾夕法尼亚大学理事会 | 抗因子d抗体及其用途 |
| CN109632924B (zh) * | 2018-12-17 | 2022-02-08 | 上海市第一人民医院 | 人黄斑新生血管性疾病的血浆脂质标记物及其应用 |
| EP3999626A4 (en) * | 2019-07-18 | 2023-11-22 | Pandorum Technologies Private Limited | PROCESSES FOR CULTURE OF STEM CELLS TO OBTAIN PRODUCTS AND THEIR MODES OF PRODUCTION |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6620915B2 (en) * | 1993-12-23 | 2003-09-16 | Icos Corporation | Monoclonal antibodies specific for integrin α-d subunit |
| WO2001004311A1 (en) | 1999-07-07 | 2001-01-18 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US20050197285A1 (en) | 1997-03-07 | 2005-09-08 | Rosen Craig A. | Human secreted proteins |
| US6472520B2 (en) | 1997-03-21 | 2002-10-29 | The Trustees Of Columbia University In The City Of New York | Rat PEG-3 promoter |
| US6410708B1 (en) | 1997-11-21 | 2002-06-25 | Genentech, Inc. | Nucleic acids encoding A-33 related antigen polypeptides |
| US7419663B2 (en) | 1998-03-20 | 2008-09-02 | Genentech, Inc. | Treatment of complement-associated disorders |
| US7192589B2 (en) | 1998-09-16 | 2007-03-20 | Genentech, Inc. | Treatment of inflammatory disorders with STIgMA immunoadhesins |
| US7282565B2 (en) | 1998-03-20 | 2007-10-16 | Genentech, Inc. | PRO362 polypeptides |
| US8088386B2 (en) * | 1998-03-20 | 2012-01-03 | Genentech, Inc. | Treatment of complement-associated disorders |
| DE69840105D1 (de) | 1997-11-21 | 2008-11-20 | Genentech Inc | Plättchen-spezifische antigene und deren pharmazeutische verwendung |
| US8007798B2 (en) | 1997-11-21 | 2011-08-30 | Genentech, Inc. | Treatment of complement-associated disorders |
| JP2002502589A (ja) | 1998-02-09 | 2002-01-29 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | ４５個のヒト分泌タンパク質 |
| US6956107B2 (en) | 1998-02-20 | 2005-10-18 | Tanox, Inc. | Inhibitors of complement activation |
| AU762050B2 (en) | 1998-02-20 | 2003-06-19 | Genentech, Inc. | Inhibitors of complement activation |
| PT1490386E (pt) | 1998-03-10 | 2008-11-24 | Genentech Inc | Novos polipéptidos e ácidos nucleicos que os codificam |
| WO2000012703A2 (en) | 1998-08-27 | 2000-03-09 | Incyte Pharmaceuticals, Inc. | Protein transport-associated molecules |
| MXPA01006057A (es) | 1998-12-16 | 2003-09-10 | Genentech Inc | Polipeptidos secretados y transmembranales y acidos nucleicos que los codifican. |
| ES2259247T3 (es) * | 1998-12-21 | 2006-09-16 | Ludwig Institute For Cancer Research | Anticuerpos frente a vegf-d truncado y sus usos. |
| EP1141284A2 (en) | 1998-12-22 | 2001-10-10 | Genentech, Inc. | Methods and compositions for inhibiting neoplastic cell growth |
| JP2004516227A (ja) | 1999-03-08 | 2004-06-03 | ジェネンテック・インコーポレーテッド | 免疫関連疾患を治療するための組成物と方法 |
| CN1637019A (zh) | 1999-03-11 | 2005-07-13 | Rmf迪克塔吉恩有限公司 | 血管粘着分子及其功能的调节 |
| US6642353B1 (en) | 1999-03-17 | 2003-11-04 | Chugai Seiyaku Kabushiki Kaisha | Peptide ligands for the erythropoietin receptor |
| WO2001036102A1 (fr) | 1999-11-02 | 2001-05-25 | Uliyanovsky Gosudarstvenny Tekhnichesky Universitet | Procede pour nettoyer un liquide des particules ferromagnetiques et dispositif correspondant |
| AU1604401A (en) | 1999-11-19 | 2001-05-30 | Human Genome Sciences, Inc. | 18 human secreted proteins |
| CA2490853A1 (en) | 1999-12-01 | 2001-06-07 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| CA2412211A1 (en) | 2000-06-23 | 2002-01-03 | Genetech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| CA2416538A1 (en) | 2000-07-20 | 2002-01-31 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| WO2004022594A2 (en) | 2002-09-06 | 2004-03-18 | Cytos Biotechnology Ag | Immune modulatory compounds and methods |
| RU2232991C1 (ru) * | 2003-04-09 | 2004-07-20 | Государственное учреждение "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского" | Способ определения функциональной активности фактора d комплемента человека |
| WO2006071856A2 (en) | 2004-12-23 | 2006-07-06 | Glycofi, Inc. | Immunoglobulins comprising predominantly a man5glcnac2 glycoform |
| NZ594285A (en) * | 2005-11-04 | 2013-02-22 | Genentech Inc | USE OF COMPLEMENT PATHWAY INHIBITOR ANTIBODY AGAINST C5a TO TREAT OCULAR DISEASES |
| US20070190057A1 (en) | 2006-01-23 | 2007-08-16 | Jian Wu | Methods for modulating mannose content of recombinant proteins |
| KR20160092061A (ko) * | 2006-11-02 | 2016-08-03 | 제넨테크, 인크. | 인간화 항-ｄ 인자 항체 |
| AR066660A1 (es) * | 2007-05-23 | 2009-09-02 | Genentech Inc | Prevencion y tratamiento de condiciones del ojo asociadas con su complemento |
| JP4349447B2 (ja) | 2007-07-19 | 2009-10-21 | トヨタ自動車株式会社 | インバータ制御装置および車両 |
-
2008
- 2008-05-21 AR ARP080102150A patent/AR066660A1/es unknown
- 2008-05-22 CN CN201410486706.3A patent/CN104367999A/zh active Pending
- 2008-05-22 WO PCT/US2008/064526 patent/WO2008147883A1/en active Application Filing
- 2008-05-22 CA CA002683498A patent/CA2683498A1/en not_active Abandoned
- 2008-05-22 KR KR1020097026746A patent/KR101540126B1/ko active IP Right Grant
- 2008-05-22 RU RU2009147744/10A patent/RU2522976C2/ru not_active IP Right Cessation
- 2008-05-22 RS RS20150223A patent/RS53901B1/en unknown
- 2008-05-22 EP EP08756130.4A patent/EP2152755B1/en active Active
- 2008-05-22 SI SI200831405T patent/SI2152755T1/sl unknown
- 2008-05-22 ES ES08756130.4T patent/ES2533242T3/es active Active
- 2008-05-22 CN CN201610972614.5A patent/CN107096029B/zh not_active Expired - Fee Related
- 2008-05-22 JP JP2010509554A patent/JP5416695B2/ja not_active Expired - Fee Related
- 2008-05-22 PT PT87561304T patent/PT2152755E/pt unknown
- 2008-05-22 AU AU2008256835A patent/AU2008256835B2/en not_active Ceased
- 2008-05-22 MX MX2009012422A patent/MX2009012422A/es active IP Right Grant
- 2008-05-22 US US12/154,466 patent/US8007791B2/en not_active Expired - Fee Related
- 2008-05-22 DK DK08756130.4T patent/DK2152755T3/en active
- 2008-05-22 PL PL08756130T patent/PL2152755T3/pl unknown
- 2008-05-22 BR BRPI0811142A patent/BRPI0811142A8/pt not_active Application Discontinuation
- 2008-05-22 CN CN200880100137.7A patent/CN101754980B/zh not_active Expired - Fee Related
- 2008-05-22 SG SG10201401404RA patent/SG10201401404RA/en unknown
- 2008-05-23 TW TW097119194A patent/TWI419704B/zh not_active IP Right Cessation
- 2008-05-23 CL CL2008001498A patent/CL2008001498A1/es unknown
- 2008-05-23 TW TW102134844A patent/TW201417829A/zh unknown
- 2008-05-23 PE PE2008000887A patent/PE20090294A1/es not_active Application Discontinuation
-
2009
- 2009-10-08 ZA ZA2009/07028A patent/ZA200907028B/en unknown
- 2009-10-13 IL IL201476A patent/IL201476A/en active IP Right Grant
-
2010
- 2010-06-13 HK HK10105890.8A patent/HK1139161A1/xx not_active IP Right Cessation
-
2011
- 2011-07-22 US US13/189,301 patent/US8268310B2/en not_active Expired - Fee Related
-
2012
- 2012-07-20 US US13/554,787 patent/US8497094B2/en active Active
-
2013
- 2013-05-16 PH PH12013500992A patent/PH12013500992B1/en unknown
- 2013-06-27 US US13/929,167 patent/US20130302333A1/en not_active Abandoned
- 2013-11-15 JP JP2013236445A patent/JP2014087346A/ja not_active Withdrawn
-
2014
- 2014-04-03 RU RU2014113046/10A patent/RU2014113046A/ru not_active Application Discontinuation
-
2015
- 2015-02-27 CY CY20151100205T patent/CY1116062T1/el unknown
- 2015-03-12 HR HRP20150281AT patent/HRP20150281T1/hr unknown
- 2015-08-14 HK HK15107851.6A patent/HK1207327A1/xx unknown
-
2016
- 2016-01-29 JP JP2016015288A patent/JP2016145205A/ja not_active Withdrawn
- 2016-02-03 US US15/014,886 patent/US20160272726A1/en not_active Abandoned
- 2016-10-27 IL IL248552A patent/IL248552A0/en unknown
-
2017
- 2017-07-28 JP JP2017146477A patent/JP2017197577A/ja active Pending
- 2017-11-29 US US15/826,016 patent/US20180079826A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20150281T1 (hr) | Prevencija i lijeäśenje stanja oka povezanih sa sustavom komplementa | |
| JP2010528047A5 (hr) | ||
| JP2020062036A5 (hr) | ||
| RU2017102514A (ru) | Гуманизированные анти-тау-антитела | |
| WO2008154251A4 (en) | C3b antibodies and methods for the prevention and treatment of complement- associated disorders | |
| HRP20211641T1 (hr) | Bispecifična protutijela anti-vegf/anti-ang-2 i njihova primjena u liječenju vaskularnih očnih bolesti | |
| HRP20151259T1 (hr) | Humanizirana protutijela anti-faktora-d i njihove uporabe | |
| JP2016504416A5 (hr) | ||
| JP2019515027A5 (hr) | ||
| JP2015503909A5 (hr) | ||
| JP2020079246A5 (hr) | ||
| WO2006055809A3 (en) | Antibodies against vascular endothelial growth factor receptor-1 | |
| JP2017535257A5 (hr) | ||
| JP2016505546A5 (hr) | ||
| RU2016137256A (ru) | АНТИТЕЛА К ФАКТОРУ КОМПЛЕМЕНТА Bb | |
| JP2018527903A5 (hr) | ||
| RU2016137110A (ru) | Антитела к компоненту комплемента с5 | |
| EA201000787A1 (ru) | Антигенсвязывающие белки | |
| JP2014534239A5 (hr) | ||
| JP2018527327A5 (hr) | ||
| RU2015144105A (ru) | Антитела к гепсидину и их применения | |
| RU2008144802A (ru) | Применение антител против ил-1 для лечения глазных расстройств | |
| JP2020536532A5 (hr) | ||
| WO2014062659A4 (en) | Methods of treating ocular diseases | |
| JP2019513726A5 (hr) |